Lantheus Holdings Inc. directors and top executives projected continued growth for the radiology supplier’s leading product despite changes in that chemical’s competitive position, an investor alleges.
A price increase for the PET scan imaging agent, Pylarify, created an undisclosed opportunity for rivals to undercut its market position, Brian Jones says on behalf of the company. Jones filed his derivative suit Oct. 31 in the US District Court for the Southern District of New York.
Pylarify sales represented 69% of 2024 revenue for Lantheus, about $1 billion of the company’s $1.5 billion total that year, according to the complaint. The agent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.